Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7

被引:47
作者
MartinezTorrecuadrada, JL
DiazLaviada, M
Roy, P
Sanchez, C
Vela, C
SanchezVizcaino, JM
Casal, JI
机构
[1] INIA, CTR INVEST SANIDAD ANIM, E-28130 VALDEOLMOS, MADRID, SPAIN
[2] INGENASA, E-28037 MADRID, SPAIN
[3] UNIV OXFORD, INST VIROL & ENVIRONM MICROBIOL, LAB MOLEC BIOPHYS, OXFORD OX1 3SR, ENGLAND
[4] UNIV ALABAMA, BIRMINGHAM, AL 35294 USA
关键词
D O I
10.1099/0022-1317-77-6-1211
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
African horsesickness virus serotype 4 (AHSV-4) outer capsid protein VP2, or VP2 and VP5 plus inner capsid protein VP7, derived from single or dual recombinant baculovirus expression vectors were used in different combinations to immunize horses, When the proteins were purified by affinity chromatography, the combination of all three proteins induced low levels of neutralizing antibodies and conferred protection against virulent virus challenge. However, purified VP2 or VP2 and VP5 in the absence of VP7 failed to induce neutralizing antibodies and protection. Immunization with non-purified proteins enhanced the titres of neutralizing antibodies. Again, the combination of the three proteins was able to confer total protection to immunized horses, which showed absence of viraemia. The antigenicity of recombinant VP2 was analysed with a collection of 30 MAbs, Both purified and unpurified recombinant VP2 proteins showed different antigenic patterns in comparison to that of VP2 on virions. An immunization experiment with four more horses confirmed these results. The vaccine described here would not only prevent the disease, but would drastically reduce the propagation of the virus by vectors.
引用
收藏
页码:1211 / 1221
页数:11
相关论文
共 29 条
[1]  
BREMER C W, 1976, Onderstepoort Journal of Veterinary Research, V43, P193
[2]   CHARACTERIZATION AND CLONING OF THE AFRICAN HORSESICKNESS VIRUS GENOME [J].
BREMER, CW ;
HUISMANS, H ;
VANDIJK, AA .
JOURNAL OF GENERAL VIROLOGY, 1990, 71 :793-799
[3]   NEUTRALIZING EPITOPES OF AFRICAN HORSESICKNESS VIRUS SEROTYPE-4 ARE LOCATED ON VP2 [J].
BURRAGE, TG ;
TREVEJO, R ;
STONEMARSCHAT, M ;
LAEGREID, WW .
VIROLOGY, 1993, 196 (02) :799-803
[4]   EXPRESSION OF THE MAJOR CORE ANTIGEN VP7 OF AFRICAN HORSESICKNESS VIRUS BY A RECOMBINANT BACULOVIRUS AND ITS USE AS A GROUP-SPECIFIC DIAGNOSTIC REAGENT [J].
CHUMA, T ;
LEBLOIS, H ;
SANCHEZVIZCAINO, JM ;
DIAZLAVIADA, M ;
ROY, P .
JOURNAL OF GENERAL VIROLOGY, 1992, 73 :925-931
[5]  
Dubourget P., 1992, Bluetongue, African horse sickness, and related orbiviruses: Proceedings of the Second International Symposium., P874
[6]  
Erasmus B. J., 1978, Equine infectious diseases IV,, P401
[7]   ASSEMBLY OF DOUBLE-SHELLED, VIRUS-LIKE PARTICLES OF BLUETONGUE VIRUS BY THE SIMULTANEOUS EXPRESSION OF 4 STRUCTURAL PROTEINS [J].
FRENCH, TJ ;
MARSHALL, JJA ;
ROY, P .
JOURNAL OF VIROLOGY, 1990, 64 (12) :5695-5700
[8]  
HOLMES IH, 1991, CLASSIFICATION NOMEN, P186
[9]   FURTHER-STUDIES ON THE EFFICACY OF AN INACTIVATED AFRICAN HORSE SICKNESS SEROTYPE 4 VACCINE [J].
HOUSE, JA ;
LOMBARD, M ;
DUBOURGET, P ;
HOUSE, C ;
MEBUS, CA .
VACCINE, 1994, 12 (02) :142-144
[10]  
INUMARU S, 1989, BIOTECHNOLOGY LIVEST, P347